載入中
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
前收盤價
US$9.82
−US$0.05 · -0.51%
盤後
US$9.83
+US$0.01 · +0.10%
10月7日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日內區間
目前US$9.82
52週區間
目前US$9.82
盤中時間採用ET。市場資料可能有所延遲。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日內區間
目前US$9.82
52週區間
目前US$9.82
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 12.5萬 USD | 12.5萬 USD |
| 毛利 | — | — | — | 12.5萬 USD | 12.5萬 USD |
| 研究與開發 | 3049.6萬 USD | 1931.4萬 USD | 2450.6萬 USD | 2078.7萬 USD | 1517.8萬 USD |
| 銷售、一般及管理費用 | 1777萬 USD | 1405.7萬 USD | 1388.5萬 USD | 1406萬 USD | 1067.3萬 USD |
| 營業費用 | 4826.6萬 USD | 3337.1萬 USD | 3839.1萬 USD | 3479.9萬 USD | 2585.1萬 USD |
| 利息收入 | 391.5萬 USD | 108.6萬 USD | 208.1萬 USD | 121.8萬 USD | — |
| 利息支出 | 211.9萬 USD | 209萬 USD | 259.5萬 USD | 170.8萬 USD | — |
| 折舊和攤銷 | 84.5萬 USD | 99萬 USD | 96萬 USD | 77.8萬 USD | 23.2萬 USD |
| 營業利益 | −4826.6萬 USD | −3337.1萬 USD | −3839.1萬 USD | −3467.4萬 USD | −2572.6萬 USD |
| 淨利 | −3818.2萬 USD | −5517.7萬 USD | −3793.9萬 USD | −1879.4萬 USD | −3612.4萬 USD |
公司資料更新於 2026年10月8日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$22.50
上漲空間 129.12%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2572.22萬0.00%2.3兆 USD0.03%US$381.03-0.40%
State Street SPDR S&P Biotech ETFXBI2253.34萬0.22%100.75億 USD0.35%US$150.23-0.44%
iShares Russell 2000 ETFIWM1651.21萬0.02%785.63億 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF871.64萬0.01%954億 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO541.81萬0.04%142.49億 USD0.24%US$355.37-1.43%
Vanguard Russell 2000 ETFVTWO476.51萬0.03%180億 USD0.06%US$112.21-1.26%
iShares Biotechnology ETFIBB451.91萬0.04%104.01億 USD0.44%US$203.34+0.12%
Schwab U.S. Small-Cap ETFSCHA366.26萬0.02%220.14億 USD0.03%US$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
